TONIX PHARMACEUTICALS HOLDING CORP. Adjustments to Additional Paid in Capital, Warrant Issued
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) reported Adjustments to Additional Paid in Capital, Warrant Issued of $26.68 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-03-12
- TONIX PHARMACEUTICALS HOLDING CORP. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-06-30 was $10.83M.
- TONIX PHARMACEUTICALS HOLDING CORP. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-03-31 was $15.85M.
- TONIX PHARMACEUTICALS HOLDING CORP. adjustments to additional paid in capital, warrant issued for the quarter ending 2020-03-31 was $451.00K.
- TONIX PHARMACEUTICALS HOLDING CORP. adjustments to additional paid in capital, warrant issued for the quarter ending 2013-12-31 was $20.83K.
- TONIX PHARMACEUTICALS HOLDING CORP. adjustments to additional paid in capital, warrant issued for fiscal 2024 was $26.68M.
- TONIX PHARMACEUTICALS HOLDING CORP. adjustments to additional paid in capital, warrant issued for fiscal 2020 was $451.00K.
- TONIX PHARMACEUTICALS HOLDING CORP. adjustments to additional paid in capital, warrant issued for fiscal 2013 was $51.00K.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|
| 2024-12-31 | $26.68M 10-K · filed 2026-03-12 | |||
| 2024-06-30 | $10.83M 10-Q · filed 2025-11-10 | $26.68M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $15.85M 10-Q · filed 2025-11-10 | |||
| 2020-12-31 | $451.00K 10-K · filed 2021-03-15 | |||
| 2020-03-31 | $451.00K 10-Q · filed 2021-11-08 | |||
| 2013-12-31 | $20.83K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $26.93K derived: sum of 2 quarters · filed 2016-03-03 | $40.56K derived: sum of 3 quarters · filed 2016-03-03 | $51.00K 10-K · filed 2016-03-03 |
| 2013-09-30 | $6.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $19.74K derived: sum of 2 quarters · filed 2013-11-13 | $30.17K 10-Q · filed 2013-11-13 | |
| 2013-06-30 | $13.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | $24.07K 10-Q · filed 2013-08-14 | ||
| 2013-03-31 | $10.44K 10-Q · filed 2013-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |